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SUMMARY
sporadic Creutzfeldt-Jakob disease (sCJD) is a rare 
neurodegenerative disease that can mimic other 
neurological disorders. We present a case of sCJD in 
a 64-year-old man that presented with corticobasal 
syndrome and survived for 3 years. He presented 
initially with dementia, hemiparkinsonism and 
alien limb phenomenon and was diagnosed with 
corticobasal degeneration, ultimately progressing to 
immobility and akinetic mutism. With a normal MrI 
1 year before onset, his neuroimaging 1 year later 
revealed abnormal Datscan, cortical and hippocampal 
atrophy with ventricular dilatation on MrI, and 
diffusion-weighted cortical ribboning and thalamic 
hyperintensity. postmortem, the patient’s brain was 
collected by the parkinson’s UK tissue Bank. prion 
protein immunohistochemistry revealed widespread 
diffuse microvacuolar staining without kuru-type 
plaques. Hyperphosphorylated tau was only found in the 
entorhinal cortex and hippocampus. this case highlights 
the clinical heterogeneity of sCJD presentation and the 
important inclusion of CJD in the differential diagnosis of 
atypical presentations of neurodegenerative disease.
BACkgRoUnd
Creutzfeldt-Jakob disease (CJD) is a transmissible 
spongiform encephalopathy caused by the patholog-
ical accumulation of aberrant prion protein (PrP), 
neuronal death and spongiform change throughout 
the brain. With an incidence of approximately 1 in 
1 000 000, CJD is a rare but fatal condition. CJD 
has several possible aetiologies: sporadic (sCJD), 
familial, iatrogenic (iCJD) and variant CJD (vCJD) 
in which PrP is transmitted to humans across a 
species barrier. Different aetiologies of CJD present 
with different clinical and pathological pheno-
types. vCJD typically has an earlier age of onset of 
approximately 26 years,1compared with sCJD in 
which only 4.5% of cases present before the age of 
40 years. vCJD typically presents with behavioural 
and psychiatric symptoms followed later by sensory 
abnormalities, ataxia and dementia. In contrast, 
iCJD and sCJD are more likely to show a clinically 
and pathologically heterogeneous picture. Histo-
logically, florid plaques are seen in vCJD, whereas 
iCJD and sCJD can show varying severities of PrP 
deposition, including ‘kuru-like’ plaques. Here we 
present a case of sCJD with an atypical presentation 
with parkinsonism, prominent early dementia and 
death within 3 years of symptom onset. We have 
been able to perform a detailed neuropathological 
investigation, and have identified this case as a rare 
subtype of this rare disease, with an unusually long 
disease course.
CASe pReSenTATion
A 64-year-old male patient who had previously been 
investigated for tension headaches presented with 
a 2-year history of memory impairment, reduced 
attention and alertness. These were present along-
side an ‘alien’ left arm with numbness and cramps, 
mild resting and postural tremor, bradykinesia, 
increased tone and reduced arm swing, more so on 
the left. He exhibited amnesia for recent events, 
executive dysfunction, anomia and apractagnosia. 
This clinical syndrome met the consensus diagnostic 
criteria for probable sporadic corticobasal degener-
ation (CBD), given the asymmetric limb bradyki-
nesia and rigidity, multiple higher cortical signs.2 
He retained only partial insight into his condition. 
He did not smoke and took minimal alcohol. The 
family history was negative for neurological disease.
inveSTigATionS
Initial Mini Mental State Examination yielded a 
score of 28/30 with deficits in recall and visuo-
spatial function. Addenbrooke’s cognitive exam-
ination yielded a score of 74/100 with prominent 
deficits in memory, fluency, language and visuospa-
tial domains. There was no evidence of rapid eye 
movement-sleep behaviour disorder, visual hallu-
cinations or fluctuating cognition, which are core 
features for the diagnosis of dementia with Lewy 
bodies (DLB).3 DaTScan revealed heterogeneous 
uptake bilaterally in the basal ganglia (figure 1A) 
more so on the right than left, which does not 
suggest Parkinson’s disease. During investigation for 
tension headaches 1 year previously, an MRI scan 
was performed which showed T2-weighted hyper-
intensities in the basal ganglia and cortical white 
matter (figure 1B,C), but an otherwise normal cere-
brum (figure 1D). By 2-years postpresentation, the 
MRI showed significant cortical and hippocampal 
atrophy on MRI (figure 1E), cortical ribboning and 
thalamic high signal on diffusion-weighted imaging 
(figure 1F).
diffeRenTiAl diAgnoSiS
An initial working differential diagnosis of CBD or 
DLB, despite a lack of DLB core clinical features,3 
was made.
TReATMenT
The patient was prescribed 10 mg daily of the 
cholinesterase inhibitor donepezil.
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oUTCoMe And follow-Up
By the next visit, at 3 months after presentation, significant defi-
cits in global cognition were noted, despite cholinesterase inhi-
bition. At 6 months, the patient had developed marked fatigue, 
word-finding difficulties and a stammer which severely impeded 
speech. Significant deficits in cognition were also present: a 
Rowland University Dementia Assessment Scale was applied, 
yielding a score of 9/30 with marked deficits in praxis, visuo-
constructional function, judgement, memory and language. 
Rivastigmine was prescribed in place of donepezil.
By 1.5 years after initial examination, his parkinsonism had 
worsened considerably with increased tremor and rigidity of the 
left hand, multiple falls, bilateral apraxia and bradykinesia of the 
hands (worse on the left), a fixed flexion deformity of the left 
hand. Reduced upgaze was noted on examination, raising the 
possibility of a diagnosis of an atypical parkinsonian syndrome. 
An initial dose of levodopa was prescribed in the form of 62.5 mg 
of levodopa, taken to times per day. However, there was no clear 
response to levodopa.
By 2 years postpresentation, the patient had become wheel-
chair-bound, was experiencing rest tremors bilaterally, postural 
instability, significant axial and limb rigidity and akinetic 
mutism. Neuroimaging showed significant cortical and hippo-
campal atrophy, ventricular dilatation, diffusion-weighted 
cortical ‘ribboning’ in the frontal and occipital cortices and 
basal ganglia hyperintensities. The patient passed away soon 
after due to causes secondary to parkinsonism. His brain was 
collected by the Parkinson’s UK Tissue Bank at Imperial College 
London.
Gross macroscopic examination revealed cortical and cere-
bellar atrophy, dilatation of the ventricular system but a well-pig-
mented substantia nigra.
Microscopically, prominent microvacuolation (figure 2A-F) 
was found in the cortex, striatum hippocampus, cerebellum 
and thalamus. Immunostaining for α-synuclein revealed no 
immunopositive structures in any region. There were frequent 
amyloid-β plaques in the frontal, temporal, entorhinal and tran-
sentorhinal cortices and striatum. Immunostaining for hyper-
phosphorylated tau revealed moderate neurofibrillary tangle 
and neuropil thread pathology in the entorhinal and transento-
rhinal cortices only. A diagnosis of spongiform encephalopathy 
was made and the case was sent to the National CJD Research 
and Surveillance Unit in Edinburgh for further neuropatholog-
ical assessment.
figure 1 Neuroimaging findings. (A) DaTscan of basal ganglia 1 year after onset showing heterogeneous but atypical reduced uptake. (B) T2-
weighted MRI showing hyperintensities in the basal ganglia (C) T2-weighted MRI showing hyperintensities in cerebral white matter at 1 year before 
onset. (D) Coronal MRI from 1 year before onset (background of chronic headaches). (E) Coronal MRI from 1 year after onset showing significant 
cortical and hippocampal atrophy and ventricular dilatation. (F) Diffusion-weighted MRI from 1 year after onset showing hyperintense cortical 
ribboning in the frontal, parietal and occipital cortices, insula and thalamus.
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Immunostaining for PrP (figure 2G-L) revealed widespread 
deposition in an intense perivacuolar pattern, without kuru-type 
plaques. Severe deposition was found throughout the cortex and 
basal ganglia, while the hippocampus, substantia nigra and cere-
bellum were relatively spared.
Western blot analysis confirmed a protease-resistant PrP with 
regional variation of the PrP isoforms present. In the frontal 
cortex, the type 2A isoform was detected with a low molecular 
weight (LMWt) band. The type 1A isoform was detected in the 
cerebellum, again with a LMWt band.
Analysis of the codon 129 polymorphism in the PrP gene 
showed that this patient was a methionine/valine heterozygote. 
Full sequence analysis of the PrP gene found no pathogenic 
mutations.
diSCUSSion
We report a case, clinically thought to be CBD, but at post-
mortem was found to be sCJD. This was a diagnosis that was 
not considered due to a long disease course, meaning that 
no cerebrospinal fluid (CSF) analysis for 14-3-3 protein was 
performed. However, the specificity of this test has been ques-
tioned. In one study, a false positive rate of approximately 30% 
was found in a population with 14-3-3 protein detected in the 
CSF who also met diagnostic criteria for probable sCJD.4 Only 
59% of this population were found to have sCJD and, interest-
ingly, none were found to have CBD pathology.4 A diagnostic 
test such real-time quaking induced conversion (RT-QuIC), with 
a similar sensitivity to 14-3-3 CSF analysis but a specificity rate 
of 98%–100%5 6 would have been a more useful test for the 
diagnosis of CJD before the patient’s death. Nonetheless, histo-
logical, immunohistochemical and biochemical analysis of this 
case confirms a diagnosis of sCJD of the met/val heterozygote 
PrP strain 2 (MV2) subtype classification. sCJD MV2 can be 
further subdivided as being predominantly cortical (C), as having 
kuru-like plaques (K), or a mixture (K+C). The pathology in 
this case was predominantly of a cortical type with absence of 
kuru-type plaque pathology, allowing a further subclassification 
into the MV2C (cortical) histotype: a relatively rare form of a 
rare disease.
While the clinical phenotype is variable, sCJD should always 
be considered in any patient with a rapidly progressing dementia. 
However, as this case shows, sCJD should also be considered in 
cases with slower progression, particularly when the symptoms 
are atypical for more common disorders such as CBD or DLB. 
sCJD MV2C has been described as having a longer clinical dura-
tion, and typically presents with ataxia, but can present with 
extrapyramidal symptoms such as parkinsonism. The present 
case showed an atypical parkinsonian syndrome with alien limb 
phenomenon, suggestive of a corticobasal syndrome. Cortico-
basal syndrome was previously reported in a case of CJD by 
Zhang et al, but this lacked pathological workup of the case.7 
Similarly, Erdal et al found corticobasal symptoms in a case of 
CJD confirmed by CSF biomarker analysis.8 Lee and colleagues 
sought to characterise the clinical syndrome in cases of sCJD 
figure 2 Neuropathology slides for the substantia nigra, caudate, cerebellum, hippocampus and cingulate gyrus. Top row: H&E stained slides, 
(A) substantia nigra, (B) caudate, (C) cerebellum, (D) hippocampus, (E) cingulate gyrus, (F) frontal cortex. Bottom row: slides immunostained with 
antibodies against prion protein, (G) substantia nigra, (H) caudate, (I) cerebellum, (J) hippocampus, (K) cingulate gyrus, (L) frontal cortex. Images taken 
with ImageProPlus V.7.0 at ×400 magnification (×1000 for F & L to show intense vacuolation in cortex). Inset are ×2000 magnification images of 
pathology from caudate, cerebellum and cingulate gyrus.
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presenting with CBS.9 Their data showed that the clinical 
syndrome is highly variable between cases. However, they found 
that the clinical features most prevalent in sCJD-CBS cases were 
alien limb phenomena, limb apraxia, rigidity, sensory loss, myoc-
lonus and cognitive impairment, all of which were present in the 
case we have presented. Marin et al reported a case of suspected 
CJD causing a clinical syndrome similar to DLB,10 however this 
report also lacked pathological confirmation of the diagnosis. 
In a previous cohort study, 46% of sCJD patients met clinical 
diagnostic criteria for DLB.11 CJD is one of the main differen-
tial diagnoses for DLB. Because cases with the MV2C subtype 
have a slower disease onset and progression than typical sCJD, 
which is usually fatal within 6–12 months, they can frequently 
be misdiagnosed.
There are multiple diagnostic neuroimaging findings for sCJD, 
some of which were present in this case and are atypical for both 
CBD and DLB. These include diffuse-weighted imaging (DWI) 
findings of high signal in the cortex and basal ganglia. Further to 
this, specific polymorphisms of sCJD show different patterns of 
DWI lesions, whereby cases that are PrP codon 129 homozygotes 
generally show focal, and heterozygotes more diffuse abnormali-
ties.12 In this case, diffuse cortical ‘ribboning’ was observed, and 
hyperintensity in the thalamus (a finding present in at least 43% 
of heterozygous sCJD).12
Our clinical diagnostic criteria for neurodegenerative disor-
ders more generally lack specificity, with a number of comorbid 
pathologies being notes in clinicopathological studies of clini-
cally defined conditions such as Alzheimer’s disease, where α-sy-
nuclein, tar DNA binding protein-43 and vascular pathology are 
found to significantly contribute to the neurodegeneration.13–15 
Though this case demonstrated the clinical diagnostic criteria for 
probable CBD, it also exhibited signs suggestive of probable CJD 
by University of California San Francisco criteria16: dementia, 
extrapyramidal features, higher cortical signs (such as apractag-
nosia) and akinetic mutism with typical neuroimaging findings. 
There is a need in the wider field to address the high error rate 
in the diagnostic criteria for neurodegenerative diseases such as 
sCJD or CBD.
learning points
 ► Sporadic Creutzfeldt-Jakob disease (sCJD) is an important 
differential diagnosis in cases of atypical neurodegenerative 
syndromes.
 ► Diffusion-weighted imaging alongside other imaging and 
cerebrospinal fluid real-time quaking induced conversion can 
aid diagnosis in atypical cases.
 ► sCJD should be considered in all cases with severe and rapid 
cerebral atrophy demonstrated on MRI.
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